Lifecore Biomedical to Participate at Upcoming Industry ConferencesGlobeNewsWire · Oct 7, 2026
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?GuruFocus · Oct 5, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)GlobeNewsWire · Oct 5, 2026
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MGGuruFocus · Oct 3, 2026
Halper Sadeh LLC is Investigating Whether LFCR and SSTI are Obtaining Fair Deals for their ShareholdersGlobeNewsWire · Sep 30, 2026
Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCRBusiness Wire · Sep 30, 2026Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.19 | -$0.19 | Beat |
| May 6, 2026 | -$0.24 | -$0.43 | Miss |
| Mar 9, 2026 | -$0.18 | -$0.19 | Miss |
| Nov 6, 2025 | -$0.30 | -$0.29 | Beat |
| Aug 7, 2025 | -$0.09 | -$0.10 | Miss |
| Apr 3, 2025 | -$0.14 | -$0.47 | Miss |